Serum tissue factor as a biomarker for renal clear cell carcinoma

ABSTRACT Purpose to determine the usefulness of serum TF as a potential marker for patients with clear cell RCC. Materials and Methods prospective study of 30 patients with clear cell RCC submitted to nephrectomy and 16 controls without clear cell RCC treated surgically for other conditions. TF is a endothelium marker that was correlated with worse prognosis in a variety of solid tumors including RCC. Serum TF was collected before surgery at the operating room and in the postoperative setting after at least four weeks. Serum samples were analyzed with a commercial ELISA kit for human TF (R&D Systems®). Results Mean preoperative serum TF levels in clear cell RCC patients and in controls were 66.8 pg/dL and 28.4 pg/dL, respectively (p<0.001). Mean postoperative serum TF levels in clear cell RCC patients were 26.3 pg/dL. In all patients with clear cell RCC postoperative serum levels of TF were lower, with a mean reduction of 41.6 pg/dL in the postoperative setting (p<0.001). Linear regression revealed that tumor size was correlated with the postoperative reduction of serum TF levels (p=0.037). Conclusions We have shown a 3-fold reduction in the median preoperative serum levels of TF in patients with clear cell RCC after surgery. We have also shown a difference of the same magnitude in the serum levels of TF compared with those of a control group of patients with benign diseases. TF appears to be a useful serum marker for the presence of clear cell RCC. Further studies are needed to validate these findings.

Saved in:
Bibliographic Details
Main Authors: Silva,Daniel D’Oliveira, Noronha,Jorge A. P., Costa,Bartira E. Pinheiro da, Zandona,Pedro Caetano Edler, Carvalhal,Gustavo F.
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Urologia 2018
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382018000100038
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1677-55382018000100038
record_format ojs
spelling oai:scielo:S1677-553820180001000382018-02-23Serum tissue factor as a biomarker for renal clear cell carcinomaSilva,Daniel D’OliveiraNoronha,Jorge A. P.Costa,Bartira E. Pinheiro daZandona,Pedro Caetano EdlerCarvalhal,Gustavo F. Kidney Neoplasms Thromboplastin Biomarkers ABSTRACT Purpose to determine the usefulness of serum TF as a potential marker for patients with clear cell RCC. Materials and Methods prospective study of 30 patients with clear cell RCC submitted to nephrectomy and 16 controls without clear cell RCC treated surgically for other conditions. TF is a endothelium marker that was correlated with worse prognosis in a variety of solid tumors including RCC. Serum TF was collected before surgery at the operating room and in the postoperative setting after at least four weeks. Serum samples were analyzed with a commercial ELISA kit for human TF (R&D Systems®). Results Mean preoperative serum TF levels in clear cell RCC patients and in controls were 66.8 pg/dL and 28.4 pg/dL, respectively (p<0.001). Mean postoperative serum TF levels in clear cell RCC patients were 26.3 pg/dL. In all patients with clear cell RCC postoperative serum levels of TF were lower, with a mean reduction of 41.6 pg/dL in the postoperative setting (p<0.001). Linear regression revealed that tumor size was correlated with the postoperative reduction of serum TF levels (p=0.037). Conclusions We have shown a 3-fold reduction in the median preoperative serum levels of TF in patients with clear cell RCC after surgery. We have also shown a difference of the same magnitude in the serum levels of TF compared with those of a control group of patients with benign diseases. TF appears to be a useful serum marker for the presence of clear cell RCC. Further studies are needed to validate these findings.info:eu-repo/semantics/openAccessSociedade Brasileira de UrologiaInternational braz j urol v.44 n.1 20182018-02-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382018000100038en10.1590/s1677-5538.ibju.2017.0007
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Silva,Daniel D’Oliveira
Noronha,Jorge A. P.
Costa,Bartira E. Pinheiro da
Zandona,Pedro Caetano Edler
Carvalhal,Gustavo F.
spellingShingle Silva,Daniel D’Oliveira
Noronha,Jorge A. P.
Costa,Bartira E. Pinheiro da
Zandona,Pedro Caetano Edler
Carvalhal,Gustavo F.
Serum tissue factor as a biomarker for renal clear cell carcinoma
author_facet Silva,Daniel D’Oliveira
Noronha,Jorge A. P.
Costa,Bartira E. Pinheiro da
Zandona,Pedro Caetano Edler
Carvalhal,Gustavo F.
author_sort Silva,Daniel D’Oliveira
title Serum tissue factor as a biomarker for renal clear cell carcinoma
title_short Serum tissue factor as a biomarker for renal clear cell carcinoma
title_full Serum tissue factor as a biomarker for renal clear cell carcinoma
title_fullStr Serum tissue factor as a biomarker for renal clear cell carcinoma
title_full_unstemmed Serum tissue factor as a biomarker for renal clear cell carcinoma
title_sort serum tissue factor as a biomarker for renal clear cell carcinoma
description ABSTRACT Purpose to determine the usefulness of serum TF as a potential marker for patients with clear cell RCC. Materials and Methods prospective study of 30 patients with clear cell RCC submitted to nephrectomy and 16 controls without clear cell RCC treated surgically for other conditions. TF is a endothelium marker that was correlated with worse prognosis in a variety of solid tumors including RCC. Serum TF was collected before surgery at the operating room and in the postoperative setting after at least four weeks. Serum samples were analyzed with a commercial ELISA kit for human TF (R&D Systems®). Results Mean preoperative serum TF levels in clear cell RCC patients and in controls were 66.8 pg/dL and 28.4 pg/dL, respectively (p<0.001). Mean postoperative serum TF levels in clear cell RCC patients were 26.3 pg/dL. In all patients with clear cell RCC postoperative serum levels of TF were lower, with a mean reduction of 41.6 pg/dL in the postoperative setting (p<0.001). Linear regression revealed that tumor size was correlated with the postoperative reduction of serum TF levels (p=0.037). Conclusions We have shown a 3-fold reduction in the median preoperative serum levels of TF in patients with clear cell RCC after surgery. We have also shown a difference of the same magnitude in the serum levels of TF compared with those of a control group of patients with benign diseases. TF appears to be a useful serum marker for the presence of clear cell RCC. Further studies are needed to validate these findings.
publisher Sociedade Brasileira de Urologia
publishDate 2018
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382018000100038
work_keys_str_mv AT silvadanieldoliveira serumtissuefactorasabiomarkerforrenalclearcellcarcinoma
AT noronhajorgeap serumtissuefactorasabiomarkerforrenalclearcellcarcinoma
AT costabartiraepinheiroda serumtissuefactorasabiomarkerforrenalclearcellcarcinoma
AT zandonapedrocaetanoedler serumtissuefactorasabiomarkerforrenalclearcellcarcinoma
AT carvalhalgustavof serumtissuefactorasabiomarkerforrenalclearcellcarcinoma
_version_ 1756428244735754240